Cover of AACR Project GENIE: Powering PrecisionMedicine through an International Consortium

 

 

 

 

 

 

AACR Project GENIE: Powering Precision Medicine through an International Consortium, June 1, 2017

AACR published a research article outlining the GENIE project.  We’re proud to share that GenomOncology team members, Clinton Miller, and Ian Mauer are listed as authors.
<p>This paper describes how GenomOncology leveraged the Knowledge Management System to load all ~19,000 GENIE cases to produce and verify several different figures.  Since the KMS is loaded with clinical content, including My Cancer Genome content, professional guidelines, and clinical trials, GenomOncology was able to provide queries by “actionability”.</p>

View PDF

 

 

AGBT 2016 Poster

Enhanced Biomarker-Based Clinical Trials Matching — Advances in Genome Biology and Technology (AGBT), September 22-24, 2016

Identifying candidates for enrollment in clinical trials with biomarker-based eligibility criteria is a complex and data analysis-intensive task. Surprisingly, it has been estimated that ~60-95% of eligible patients go unidentified; for patients this means a missed opportunity at a potential cure, and for the drug approval system, a huge loss of time and resources.

To solve this problem, GenomOncology has developed a custom clinical trial curation tool used by the team at My Cancer Genome (MCG) to curate biomarker-based and disease-type eligibility criteria, which is party of our Knowledge Management System (KMS). The result of this process is a database where each clinical trial exists as a set of content based assertions, that interacts with the GO Clinical Workbench, in which patients with particular alterations and disease combinations are matched to the appropriate clinical trials in the most accurate manner possible.

View PDF

 

img_ASHG

Multi-modal Report Summary for AML: Combining NGS and Cytogenetics Data to Enable Therapeutic Decision Making — American Society of Human Genetics Meeting, October 7, 2015

Acute myeloid leukemia (AML) is a clonal disorder of the blood forming cells characterized by accumulation of immature blast cells in the bone marrow and peripheral blood. It is a heterogeneous disease, and as such, its molecular footprint varies. It is therefore important to test for key genetic biomarkers for both prognostic and treatment purposes. Choice of treatments can benefit from genetic marker based risk stratification.
View PDF
PubMedLogo

Somatic mutation spectrum of non-small cell lung cancer in African Americans: a pooled analysis. J Thorac Oncol. 2015 Aug 21. [Epub ahead of print]

View Abstract at PubMed
img_ValidationReportingFramework

Standardized NGS-based Assay Validation: GO Validation Reporting Framework – Cancer Genome Consortium Meeting August 3, 2015

Cancer panels use next generation sequencing (NGS) technology to identify clinically relevant variants in cancer-related genes in order to impact patient care. Validating cancer panels for clinical testing is challenging due to the large number of variant positions covered by the panels and the low variant allelic frequency (VAF) that is often present in somatic cancer. The goal of this project was to utilize GenomAnalytics (GenomOncology, Cleveland, OH) software to facilitate the clinical validation of a 50 cancer-gene NGS panel.
View PDF
PubMedLogo

Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing. J Clin Oncol. 2015 Jun 10; 33(17):1966-73.

View Abstract at PubMed